U.S. Nebulizer Market Size, Share & Trends Analysis Report By Type (Jet, Mesh, Ultrasonic), By Application (COPD, Asthma), By End-use (Hospitals & Clinics, Emergency Centers), And Segment Forecasts, 2024 - 2030

U.S. Nebulizer Market Size & Trends

The U.S. nebulizer market size was valued at USD 287.2 million in 2023 and is projected to grow at a CAGR of 5.4% from 2024 to 2030. The increasing prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), has triggered the need for nebulizers. Furthermore, the increasing geriatric population, nebulizer technology advancements, and home healthcare infrastructure are fueling the market growth.

According to the statistics published by the CDC, approximately 14.2 million, or 6.5 % of the total adults in the U.S., were diagnosed with COPD in 2021. In addition, a higher prevalence of the disease was observed among women and adults aged 65 and above. According to an article published by the U.S. Census Bureau in May 2023, there were about 55.8 million people in the U.S. aged 65 and above. This high prevalence of people with COPD and increasing geriatric population is expected to drive demand for nebulizers in the country.

Nebulizers are a convenient and portable way for patients to receive respiratory therapy at home, eliminating the need for frequent hospital visits. This is especially useful for patients with chronic respiratory disease who require regular medication. According to the National Center for Health Statistics, approximately 8.7% of people in the U.S. suffered from asthma in 2022. In addition, chronic lower respiratory diseases other than asthma led to approximately 40.7% deaths per 100,000 population in the country. The development of home-based healthcare infrastructure is expected to help in availing nebulizers and emergency assistance for these patients and foster further growth in the market.

Furthermore, rising healthcare costs are putting a strain on healthcare financing. Compared to other therapies, such as metered-dose inhalers (MDIs), nebulizers offer a cost-effective solution to deliver drugs to the lungs. This cost-effectiveness is becoming increasingly important to patients and healthcare professionals, making nebulizers an attractive choice. This is anticipated to drive market growth.

Type Insights

Jet dominated the market and accounted for a share of 66.0% in 2023 attributable to their easy availability as compared to the other alternatives that are available in the market to serve the larger group of patients. Additionally, its effectiveness in administering medicine to the lower respiratory tract make the devices preferred by healthcare workers.

Mesh is expected to register the fastest CAGR of 5.8% over the forecast period owing to its advanced technology that provides fast and highly effective drug delivery when compared to that of a usual nebulizer. For instance, according to a study published by the National Library of Medicine in July 2019, in a randomized controlled trial, patients treated with vibrating mesh nebulizers (dry or humidified) experienced fewer ICU days compared to the patients treated with metered dose inhalers (dry or humidified. In addition, their portability, quiet operation, and capacity to deliver various medicines suitable for children and adults are anticipated to drive market growth.

Application Insights

The asthma segment dominated the market in 2023 and accounted for a market share of 40.0% driven by the high prevalence of asthma, which requires regular and effective administration of drugs for disease management. Nebulizers are especially useful for asthmatics, including young children and the elderly, who may find it difficult to use inhalers effectively. Furthermore, advancement in nebulizer technology improves the treatment effectiveness and has contributed significantly to the growth of this segment.

The COPD segment is expected to grow significantly over the forecast period. The aging population is an important factor, as the prevalence of COPD increases with age. In addition, increased levels of air pollution and smoking contribute to an increase in the number of people diagnosed with COPD requiring nebulizer treatment. According to a study published by the National Library of Medicine in July 2020, COPD was the fourth largest cause of death in the U.S. In addition, the study also suggested that nebulizers provide ease of use for patients with no requirements for forceful inspiratory maneuvers or complex hand-breath coordination compared to inhalers. The increasing prevalence of COPD is, therefore, expected to drive demand for nebulizers over the forecast period.

End Use Insights

The hospitals and clinics segment dominated the market in 2023. The hospitals and clinics provide a controlled environment with physicians trained to administer nebulized drugs, especially for critical cases or patients who require intensive care. Furthermore, reimbursement policies often favour treatment provided in these facilities and make nebulizers in hospitals and clinics a cost-effective option for healthcare providers and patients.

The others segment, consisting of home healthcare, is expected to grow at the fastest CAGR over the forecast period from 2024 to 2030. The increasing advancements in technology and efforts to prevent hospitalization are expected to drive the growth of this segment. For instance, in October 2020, AireHealth developed connected nebulizers to help patients monitor their respiratory conditions at home, which is likely to help in preventing hospitalization and foster segmental growth.

Key U.S. Nebulizer Company Insights

Some key companies in the U.S. nebulizer market includes OMRON Healthcare, Inc., GE Healthcare, Koninklijke Philips N.V., Allied Healthcare, and others. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions and partnerships with other major companies.

• OMRON Healthcare, Inc., is a global company developing medical devices for health monitoring and therapy. The company offers several devices, including nebulizers, blood pressure monitors, pedometers, inhalers, and body composition monitors.

• Allied Healthcare is a company that provides advanced medical equipment and supplies to both professional healthcare professionals and individual patients. Their product portfolio includes essential equipment for a variety of disciplines, from respiratory therapy with nebulizers to patient monitoring devices that ensure patient well-being.

Recent Developments

• In July 2020, OMRON Healthcare, Inc. launched OMRON NE C106, an all-age-group compatible nebulizer, expanding its portfolio of compressor nebulizers.

• In June 2020, Renovion Raised USD 8.1 million to help in advancing ARINA-1 Nebulizer Therapy. The funding is helped the company in launching the Phase 2/3 pivotal trial in the U.S.

U.S. Nebulizer Market Report Scope

U.S. Nebulizer Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. nebulizermarket report based on type, application, and end use:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Jet

  • Mesh

  • Ultrasonic

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • COPD

  • Asthma

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals & Clinics

  • Emergency Centers

  • Others (Home Healthcare, etc.)